Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Advanced Proteome Therapeutics Corporation (V:APC)

Business Focus: Shell Companies

Sector:  Financials Industry:  Investment Holding Companies
 
Company Contact
Address: suite 104 8337 Eastlake Dr.
BURNABY BC V5A 4W2
Tel: 1-604-6903797
Website: https://www.advancedproteome.com
IR: See website
Key People
Paul Woodward
Chief Executive Officer, Director
Kenneth Clifford Phillippe
Chief Financial Officer
 
Business Overview
Advanced Proteome Therapeutics Corporation is actively seeking additional funds to advance its core technologies for partnering and other potential revenue streams. It is not engaged in any activity.
Financial Overview
For the nine months ended 30 April 2023, Advanced Proteome Therapeutics Corporatn revenues was not reported. Net loss applicable to common stockholders totaled $2M vs. income of $836K. Net loss reflects FV Adjustments of Financial Investments decrease of 98% to $23K (income), Interest expense increase of 31% to $29K (expense), Regulatory Fees increase of 39% to $23K (expense).
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $0.00M as of Apr 30, 2023
EBITDA (TTM): -$1.29M as of Apr 30, 2023
Net annual income (TTM): -$2.79M as of Apr 30, 2023
Free cash flow (TTM): -$1.28M as of Apr 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 41,127,080 as of Apr 30, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization